Acute Kidney Injury in Adult Patients With Hepatocellular Carcinoma After TACE or Hepatectomy Treatment

Mou, Zhixiang; Guan, Tianjun; Chen, Lan

doi:10.3389/fonc.2022.627895

Cited by 3 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High pre-treatment albumin/bilirubin grade and aspartate aminotransferase-to-platelet index are associated with poorer outcomes [ 79 , 80 ]. Age, diabetes mellitus (DM), and the number of TACE sessions are risk factors for acute kidney injury—which increases mortality 4.74-fold—in patients with HCC after TACE [ 81 ]. Recently, an albumin-based algorithm was proposed [ 82 ].…”

Section: Tacementioning

confidence: 99%

Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma

Podlasek

Abdulla

Bröering

et al. 2023

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is responsible for 90% of primary hepatic cancer cases, and its incidence with associated morbidity and mortality is growing worldwide. In recent decades, there has been a revolution in HCC treatment. There are three main types of locoregional therapy: radiofrequency ablation, transarterial chemoembolisation, and transarterial radioembolisation. This article summarises recent advances in locoregional methods.

show abstract

Section: Tacementioning

confidence: 99%

Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma

Podlasek

Abdulla

Bröering

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Several meta-analyses reveal benefits of combined therapy TACE plus local therapies without evidence of increase in complications rate related to local therapies. [122][123][124][125][126][127][128][129][130][131] Two clinical trials examined TACE plus microwave or radiofrequency ablation. The first was performed by Sheta et al 87 including 50 patients with Child-Pugh A-B disease and tumor lesion >4 cm confined to one hepatic lobe.…”

Section: Tace Versus Tace Plus Another Local Therapymentioning

confidence: 99%

“…Several meta-analyses reveal benefits of combined therapy TACE plus local therapies without evidence of increase in complications rate related to local therapies. 122 123 124 125 126 127 128 129 130 131…”

Section: Scales and Scores To Support Decision-makingmentioning

confidence: 99%

Bland Embolization and Transarterial Chemoembolization in Hepatocarcinoma

Holguín Holguín,

Toro Gutierrez,

Bustamante-Cristancho

et al. 2023

Digestive Disease Interventions

View full text Add to dashboard Cite

Hepatocarcinoma (HCC) is the main cause of morbidity and mortality worldwide in patients with cirrhosis. Eighty percent of cases worldwide are due to infections with hepatitis B and C viruses, but nonalcoholic steatohepatitis (NASH) is projected to be an important etiology. It is usually diagnosed in advanced stages, only 15% of patients are surgical candidates, and up to 35% can receive only supportive care. This pathology has changed over time with the significant advances in treatment alternatives that can improve life expectancy for patients who are not surgical candidates. Therapeutic alternatives are available based on staging according to different models and the Barcelona Clinic Liver Cancer (BCLC) staging system. Systemic pharmacological options (neoadjuvant, adjuvant, and hormonal therapy), surgical options, and locoregional therapies have been developed; all these interventions have been directed to increase the life expectancy of some patients with variable results. Regional therapies include transarterial embolization (TAE) or bland embolization, transarterial infusion chemotherapy, conventional transarterial chemoembolization (TACE), drug-eluting bead transarterial chemoembolization (DEB-TACE), and transarterial radioembolization, with no substantial difference in outcomes between patients treated with TACE and those receiving DEB-TACE, but benefits of lower systemic adverse effects and improved of quality-adjusted life years measure with DEB-TACE. With the addition of immunotherapy to these interventions, the outcomes are expected to be even more impactful on main outcomes such as survival and disease-free survival.

show abstract

Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection

Doi,

Yasuda,

Nagai

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

AimPersistent acute kidney injury (AKI) has not been investigated in patients undergoing liver resection. We aimed to identify the predictors of persistent AKI, its effect on postoperative outcomes and long‐term renal function in patients following liver resection, and its impact on survival in patients with hepatocellular carcinoma (HCC).MethodsWe examined 990 patients who underwent liver resection, including a subgroup analysis of 384 patients with curative resection for initial HCC. Persistent AKI was defined as residual impairment of serum creatinine ≥ 0.3 mg/dL or ≥50% from baseline 1 month after surgery.ResultsThe persistent AKI group had significantly worse postoperative outcomes, including overall morbidity, major morbidity, longer hospital stay, and 90‐day mortality. In the subgroup analysis of patients with HCC, persistent AKI was associated with a significantly poorer overall survival (OS) rate (p < 0.001), and the multivariate analysis confirmed persistent AKI as an independent poor prognostic factor for OS (p = 0.005). The long‐term postoperative estimated glomerular filtration rate decline was significantly greater in the persistent AKI group than in the no AKI and transient AKI groups (p < 0.001 for both). Chronic kidney disease, albumin–bilirubin grade ≥2, and anatomical resection were independent predictors of persistent AKI (p = 0.001, p = 0.039, and p = 0.015, respectively).ConclusionsPersistent AKI adversely affects postoperative outcomes and long‐term renal function in patients undergoing liver resection. Furthermore, it is associated with poor prognosis in patients with HCC. Therapeutic strategies to prevent persistent AKI are critical for improving postoperative outcomes in these patients.

show abstract

Acute Kidney Injury in Adult Patients With Hepatocellular Carcinoma After TACE or Hepatectomy Treatment

Cited by 3 publications

References 43 publications

Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma

Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma

Bland Embolization and Transarterial Chemoembolization in Hepatocarcinoma

Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection

Contact Info

Product

Resources

About